Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $251.06

IQVIA Holdings Inc. (NYSE:IQV) has received an average recommendation of “Moderate Buy” from the eighteen analysts that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $241.75.

Several equities analysts have recently issued reports on IQV shares. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. Morgan Stanley boosted their target price on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Barclays dropped their price target on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Friday. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Citigroup lowered their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of IQV. Claret Asset Management Corp grew its holdings in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after buying an additional 49 shares in the last quarter. Versant Capital Management Inc raised its holdings in IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after acquiring an additional 53 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its stake in IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares in the last quarter. Private Advisor Group LLC grew its position in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares in the last quarter. Finally, Brookstone Capital Management increased its holdings in shares of IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

IQVIA Price Performance

Shares of NYSE:IQV opened at $187.50 on Thursday. The company has a market cap of $31.93 billion, a PE ratio of 23.85, a P/E/G ratio of 1.90 and a beta of 1.37. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The firm has a 50-day simple moving average of $228.03 and a 200 day simple moving average of $209.77. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts anticipate that IQVIA will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.